Endurance Applications

What people mean by endurance peptides

Two mitochondrial peptides come up whenever endurance athletes or lifters talk about "mito peptides": MOTS-c and SS-31 (elamipretide). The pitch is that because they act on mitochondria, the parts of the cell that make most of its ATP during sustained exercise, they should help people go longer or recover faster. That's a reasonable hypothesis. Testing it in people is a different matter, and as of October 2026 nobody has done it in healthy athletes.

This page sorts the claims by the kind of evidence behind them. For a closer look at specific aerobic markers, see our page on aerobic capacity enhancement.

Where mitochondria fit in endurance

VO2max is the most oxygen your body can use per minute during an all-out effort. In exercising humans it's limited mainly by how much oxygen the heart and blood can deliver, not by how much the muscle can extract. Training raises it mostly by raising maximal cardiac output, according to a widely cited 2000 review by Bassett and Howley in Medicine & Science in Sports & Exercise.

Mitochondria matter more for what happens below that ceiling. Endurance training increases mitochondrial enzyme activity in muscle, so you burn more fat and build up less lactate at the same workload. That shows up as a higher lactate threshold: the pace you can hold before lactate starts climbing quickly. The same review calls speed at lactate threshold the best physiological predictor of distance-running performance.

So a compound that improved mitochondrial density or efficiency would, in theory, act on the lactate-threshold side more than on VO2max. That's worth remembering when a peptide is pitched as a VO2max booster.

MOTS-c: mouse treadmill data, no human dosing studies

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. In cell and mouse studies it activates AMPK, the cell's energy sensor (see how peptides are thought to activate AMPK).

The endurance claim traces mostly to one paper. In a 2021 Nature Communications study, Reynolds and colleagues injected mice daily with MOTS-c at 5 or 15 mg/kg/day into the abdominal cavity. Young mice on the higher dose ran longer and farther on a treadmill test after 10 days of treatment, though not after 7 days. In one experiment, every mouse on the higher dose reached the final sprint stage, against 16.6% of mice in the lower-dose and control groups. Grip strength didn't change. Old mice given MOTS-c three times a week, starting late in life, also kept more physical capacity than untreated mice.

The same paper had a human component, and it's often misread. Ten sedentary young men did a cycling session, and their own MOTS-c levels rose about 11.9-fold in muscle and 1.6-fold in blood. Nobody was given MOTS-c. The result shows that exercise raises the body's own peptide. It doesn't show that injecting more of it improves performance.

What's missing is the step in between. As of October 2026, no published study has given native MOTS-c to people. The only human trials of anything MOTS-c-like used CB4211, an analog developed by CohBar. In its 2021 Phase 1b, 20 adults with obesity and fatty liver received 25 mg of CB4211 or placebo by subcutaneous injection once daily for four weeks. Liver enzymes fell more on CB4211, liver fat fell by a similar amount in both groups, and injection-site reactions were the main side effect. In 2023 CohBar said the formulation wasn't suitable for further development, and that November it moved to liquidate the company after a planned merger fell through. CB4211 was never tested on exercise.

For more on the peptide's performance story, see our MOTS-c endurance article.

SS-31 (elamipretide): walk-test trials in mitochondrial disease

SS-31 binds cardiolipin, a lipid in the inner mitochondrial membrane, and is meant to stabilize the machinery that makes ATP. Unlike MOTS-c, it has been tested in people, though only in rare mitochondrial diseases. The main endpoint in several trials was the 6-minute walk test (6MWT), which is the closest thing this literature has to an endurance measure.

A later post hoc analysis of MMPOWER-3 found a better walk-test response in people whose disease comes from nuclear DNA defects affecting mitochondrial DNA maintenance (mostly POLG). It also found an unusually strong placebo response in another large subgroup. That analysis led to NuPOWER, a Phase 3 trial using 60 mg. Subgroup findings after a failed trial are hypotheses to test, not results.

SS-31 reached the market anyway. On September 19, 2025, the FDA granted accelerated approval to elamipretide as Forzinity for Barth syndrome in patients weighing at least 30 kg. The approval rests on knee-extensor muscle strength, which rose during the open-label extension of SPIBA-201 but not during its randomized phase. Walking distance wasn't the basis. The label dose is 40 mg by subcutaneous injection once daily, and FDA requires a confirmatory placebo-controlled trial. As of October 2026, Forzinity is a prescription medicine for that one rare disease. Research-use vials sold online are not the same product.

None of these trials enrolled healthy people or athletes. A drug that helps badly impaired mitochondria may do nothing measurable in muscle that already works normally.

What users report

Community reports fill the space the trials leave empty, and they should be read as reports rather than data. In a 2026 GLP-1 Forum thread on MOTS-c, several users describe steadier energy during training and less fatigue afterward. One says they can run longer and faster. Others call the effect subtle.

Doses in that thread vary widely. One user describes starting at 1 mg three times a week and later moving to about 15 mg a week in a four-week block. Another describes 5 mg about three times a week before training. A third reports 5-10 mg a day in four- to five-week cycles. One poster calls it the usual approach to run SS-31 for a few weeks before adding MOTS-c. None of these schedules has been tested in a trial.

Injection-site itching and swelling are the most common complaint in the thread, and a few posters relay secondhand accounts of serious allergic reactions. Those accounts are unverified, but they line up with the FDA's warning about allergic reactions to Forzinity and the injection-site reactions seen with CB4211.

These reports have the usual limits. There's no placebo, and the content of gray-market vials is unknown. Several posters in that thread also use retatrutide, which makes it hard to credit any change to MOTS-c. The distance between "users feel more energy" and "mice ran longer on a treadmill" is large, and no human trial has measured endurance on MOTS-c to close it.

Sport rules

MOTS-c is named on the WADA 2026 Prohibited List under S4.4.1 (activators of AMPK), so it's prohibited at all times, in and out of competition, for tested athletes. Elamipretide isn't named on the list. As of October 2026, we couldn't confirm whether another section covers it now that it's an approved drug. Our page on peptides and sport rules has the details.

What we still don't know

• Whether MOTS-c changes endurance in people at any dose. No published human study has tested it.
• Whether SS-31 does anything for healthy muscle. Every trial so far has been in mitochondrial disease.
• How safe long-term use is for healthy people; see our page on long-term health implications.
• Whether NuPOWER and the Forzinity confirmatory trial will support the subgroup and open-label signals.